Status:
COMPLETED
A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy
Lead Sponsor:
Jazz Pharmaceuticals
Conditions:
Narcolepsy
Eligibility:
All Genders
18+ years
Brief Summary
The rationale for the patient-centric, prospective, observational, non-interventional study design of JZP258-402 is to evaluate the transition experience of participants with narcolepsy treated with o...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Male or female, aged 18 years or older
- Diagnosis of type 1 or type 2 narcolepsy by a physician
- Active prescription for Xyrem with a stable treatment regimen for at least 2 consecutive months
- Transitioning from Xyrem to Xywav within the next or past 7 days (- 7 days or + 7 days from the first dose of Xywav)
- Able to read and understand English
- Able to access to a computer/smart phone with internet connection
- Not currently a Jazz Pharmaceuticals employees or an immediate family member of a Jazz employee
- Willing and able to comply with the study schedule
- Willing and able to provide electronically written informed consent
Exclusion
Key Trial Info
Start Date :
April 9 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 24 2022
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT04803786
Start Date
April 9 2021
End Date
February 24 2022
Last Update
June 30 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jazz Pharmaceuticals Clinical Site
Palo Alto, California, United States, 94304